Oxaliplatin and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Oxaliplatin (oxaliplatin), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Paclitaxel, and have Inflammatory bowel disease.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Oxaliplatin. It is created by eHealthMe based on reports of 71,972 people who have side effects when taking Oxaliplatin from the FDA, and is updated regularly.

What is Oxaliplatin?

Oxaliplatin has active ingredients of oxaliplatin. It is often used in colon cancer. eHealthMe is studying from 72,058 Oxaliplatin users. Check the latest studies of Oxaliplatin.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 592 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

On Aug, 04, 2026

71,972 people reported to have side effects when taking Oxaliplatin.
Among them, 35 people (0.05%) have Progressive multifocal leukoencephalopathy.

Could Oxaliplatin cause Progressive multifocal leukoencephalopathy?

Among these 35 people:

How long have people been on Oxaliplatin when they have Progressive multifocal leukoencephalopathy? *

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Oxaliplatin? *

female: 73.53 %
male: 26.47 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Oxaliplatin? *

What are other drugs people take besides Oxaliplatin? *

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

Jc Virus Infection: 16 people, 45.71%
Lymphopenia (an abnormally low level of lymphocytes in the blood): 11 people, 31.43%
Infection Reactivation: 9 people, 25.71%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 5 people, 14.29%
Leukopenia (less number of white blood cells in blood): 5 people, 14.29%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 4 people, 11.43%
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system): 3 people, 8.57%
Confusional State: 3 people, 8.57%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 3 people, 8.57%
Memory Loss: 3 people, 8.57%

What are the existing conditions these people have? *

Inflammatory Bowel Disease: 7 people, 20.00%
Oesophageal Carcinoma (cancer tumour of oesophagus): 5 people, 14.29%
Diffuse Large B-Cell Lymphoma Stage Ii (cancer of b cells, a type of white blood cell-stage ii): 5 people, 14.29%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 5 people, 14.29%
Diffuse Large B-Cell Lymphoma Recurrent (recurrent cancer of b cells, a type of white blood cell): 4 people, 11.43%
Bone Marrow Conditioning Regimen: 4 people, 11.43%
Thymoma Malignant (a cancerous tumour originating from the epithelial cells of the thymus): 2 people, 5.71%
Metastases To Liver (cancer spreads to liver): 2 people, 5.71%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 5.71%
Thymoma (a tumour originating from the epithelial cells of the thymus): 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Oxaliplatin and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oxaliplatin:

Oxaliplatin (72,058 reports)

Progressive multifocal leukoencephalopathy treatments and more:

Progressive multifocal leukoencephalopathy (13,731 reports)

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Progressive multifocal leukoencephalopathy in Oxaliplatin

Expand to all the drugs that have ingredients of oxaliplatin:

Progressive multifocal leukoencephalopathy and drugs with ingredients of oxaliplatin

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Oxaliplatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (592 drugs)

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (921 conditions)

Related publications that referenced our studies

Kim HJ, An SH, Cho YH, Kim SY, Lee HG, Yoon SY, "Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer", Acta Oncologica, 2013 Aug .
Wang JH, King TM, Chang MC, Hsu CW, "Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis", World journal of gastroenterology: WJG, 2012 Oct .
Kim HJ, An SH, Cho YH, Kim SY, Lee HG, Yoon SY, "Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer", Acta Oncologica, 2013 Aug .
Wang JH, King TM, Chang MC, Hsu CW, "Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis", World journal of gastroenterology: WJG, 2012 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on oxaliplatin (the active ingredients of Oxaliplatin) and Oxaliplatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.